Literature DB >> 19561530

Efficacy of 5-ASA in the treatment of colonic diverticular disease.

Luigi Gatta1, Nimish Vakil, Dino Vaira, Alberto Pilotto, Margherita Curlo, Giuseppe Comparato, Gioacchino Leandro, Umberto Ferro, Maurizio Lera, Sergio Milletti, Francesco Di Mario.   

Abstract

OBJECTIVE: To assess the therapeutic efficacy of 5-aminosalicylic acid (5-ASA) in patients with colonic diverticular disease performing a systematic review of the literature. DATA SOURCES: Cochrane Trial Register (until Issue 4, 2008), Medical Literature Analysis and Retrieval System Online (1966 to October 1, 2008), Excerpta Medica Database (1980 to October 1, 2008), and abstracts from the major US, European, and Asian gastroenterology conferences. Expert opinions sought and reference lists of identified studies and any relevant published reviews checked. STUDY SELECTION: Randomized controlled trial (RCT) or a controlled clinical trial with a parallel group design using 5-ASA as 1 treatment arm.
RESULTS: Six RCTs enrolling 818 patients were found: 3 were performed in patients with uncomplicated diverticulitis, and the remaining in patients with symptomatic uncomplicated diverticular disease. The results of these studies showed that patients treated with 5-ASA had significantly better outcomes and that also mesalazine scheduled daily was superior to cyclic administration to prevent relapse of diverticular disease. However, several of these studies have not included an endoscopy at the start of the study and when patients had recurrences.
CONCLUSIONS: From this systematic review, it seems that 5-ASAs may have a role in patients with colonic diverticular disease. However, high-quality well-designed RCTs are necessary to confirm these initial observations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19561530     DOI: 10.1097/MCG.0b013e3181a15864

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  8 in total

1.  Long-term treatment with mesalazine in patients with symptomatic uncomplicated diverticular disease.

Authors:  Luigi Gatta; Francesco Di Mario; Margherita Curlo; Dino Vaira; Alberto Pilotto; Paolo Lucarini; Maurizio Lera; Kajo Enkleda; Angelo Franzé; Carmelo Scarpignato
Journal:  Intern Emerg Med       Date:  2011-01-29       Impact factor: 3.397

2.  Medical treatment of colonic diverticular disease: are we sure the aim is right?

Authors:  Gabrio Bassotti; Vincenzo Villanacci
Journal:  Intern Emerg Med       Date:  2011-03-23       Impact factor: 3.397

3.  Management of colonic diverticular disease with poorly absorbed antibiotics and other therapies.

Authors:  Federico Sopeña; Angel Lanas
Journal:  Therap Adv Gastroenterol       Date:  2011-11       Impact factor: 4.409

Review 4.  Diverticular disease: reconsidering conventional wisdom.

Authors:  Anne F Peery; Robert S Sandler
Journal:  Clin Gastroenterol Hepatol       Date:  2013-05-10       Impact factor: 11.382

Review 5.  Pathophysiology and Therapeutic Strategies for Symptomatic Uncomplicated Diverticular Disease of the Colon.

Authors:  Eleonora Scaioli; Antonio Colecchia; Giovanni Marasco; Ramona Schiumerini; Davide Festi
Journal:  Dig Dis Sci       Date:  2015-10-12       Impact factor: 3.199

6.  Intermittent treatment with mesalazine in the prevention of diverticulitis recurrence: a randomised multicentre pilot double-blind placebo-controlled study of 24-month duration.

Authors:  F Parente; S Bargiggia; A Prada; A Bortoli; A Giacosa; B Germanà; A Ferrari; G Casella; G De Pretis; G Miori
Journal:  Int J Colorectal Dis       Date:  2013-06-12       Impact factor: 2.571

Review 7.  Evaluation and Medical Management of Uncomplicated Diverticulitis.

Authors:  Sean J Langenfeld
Journal:  Clin Colon Rectal Surg       Date:  2021-02-24

8.  Mesalazine for People with Diverticular Disease: A Systematic Review of Randomized Controlled Trials.

Authors:  Andrea Iannone; Marinella Ruospo; Germaine Wong; Michele Barone; Mariabeatrice Principi; Alfredo Di Leo; Giovanni F M Strippoli
Journal:  Can J Gastroenterol Hepatol       Date:  2018-09-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.